Abbott (NYSE: ABT) completed the acquisition of Cardiovascular Systems, Inc., a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s atherectomy system prepares vessels for angioplasty or stenting to restore blood flow. Pursuant to the terms of the merger agreement, upon completion of the acquisition, CSI became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition, April 27 was the last day of trading of CSI shares on the Nasdaq Stock Market.
Abbott is a global healthcare leader with a portfolio of life-changing technologies that spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. The company has 115,000 employees in more than 160 countries.
FinSMEs
01/05/2023